Welcome to Psychiatryai.com: Latest Evidence - RAISR4D

Estimated reading time for CME/CPD: 1 min

When ‘Cannabidiol’ Is Not Cannabidiol – And Why It Matters for Clinicians and Patients

AI Summary
  • Products labelled "cannabidiol" often have incorrect CBD levels, contaminants, or undisclosed THC, risking efficacy and safety for patients.
  • Clinicians must verify product composition, source, and lab testing to guide dosing and avoid adverse interactions with other medications.
  • Greater regulation, standardised testing, and clearer labelling are urgently needed to protect patients and enable evidence-based CBD prescribing.
Summarise with AI (MRCPsych/FRANZCP)

Braz J Psychiatry. 2026 Sep 18. doi: 10.47626/1516-4446-2026-5187. Online ahead of print.

NO ABSTRACT

PMID:42758935 | DOI:10.47626/1516-4446-2026-5187

Document this CPD

Share Evidence Blueprint

QR Code

Save to Google Notes

Search Google Scholar

Save as PDF

My Revision List

close chatgpt icon
ChatGPT

Enter your request.

← →
RAISR4D CME/CPD Evidence Nodes
Swipe to navigate RAISR4D CME/CPD evidence nodes.
CME/CPD